Abstract
Circulating tumor DNA (ctDNA) is emerging as a promising biomarker for cancer diagnosis. However, the system to detect gene mutations with very low frequencies from plasma remains to be established in terms of technical aspects of sequencing technologies and cost for universal use. One strategy is to employ a cancer sequencing panel to detect mutations in a primary tumor in a time- and cost-effective manner, and subsequently assess these mutations with a digital PCR technology from plasma ctDNA. This strategy enables the accurate detection of low frequency mutations (i.e., less than 1% allele frequency) from ctDNA, since both comprehensive coverage of genes and quantitative mutation detection with very low frequencies are required for cancer diagnosis from plasma samples. Here, we present a pipeline can be used to detect mutations from plasma ctDNA with very low allele frequencies using a next-generation sequencing technology for comprehensive coverage of primary tumors and droplet digital PCR for sensitive detection from plasma ctDNA.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Primrose JN, Perera R, Gray A et al (2014) Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 311:263–270
Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra224
Kuang Y, Rogers A, Yeap BY et al (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15:2630–2636
Morelli MP, Overman MJ, Dasari A et al (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26:731–736
Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112
Sacher AG, Paweletz C, Dahlberg SE et al (2016) Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2(8):1014–1022
Sakai K, Horiike A, Irwin DL et al (2013) Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 104:1198–1204
Spindler KG, Appelt AL, Pallisgaard N et al (2013) KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer 109:3067–3072
Spindler KL, Pallisgaard N, Vogelius I et al (2012) Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18:1177–1185
Tabernero J, Lenz HJ, Siena S et al (2015) Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 16:937–948
Taniguchi K, Uchida J, Nishino K et al (2011) Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17:7808–7815
Yamada T, Iwai T, Takahashi G et al (2016) Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. Cancer Sci 107(7):936–943
Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990
Pereira E, Camacho-Vanegas O, Anand S et al (2015) Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One 10:e0145754
Tie J, Wang Y, Tomasetti C et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra392
Wimberger P, Roth C, Pantel K et al (2011) Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer 128:2572–2580
Perrone F, Lampis A, Bertan C et al (2014) Circulating free DNA in a screening program for early colorectal cancer detection. Tumori 100:115–121
Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586
Vogelstein B, Papadopoulos N, Velculescu VE et al (2013) Cancer genome landscapes. Science 339:1546–1558
Sato KA, Hachiya T, Iwaya T et al (2016) Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel. PLoS One 11:e0146275
Pellerin C, Mckercher G, Aprikian AG et al (2016) A simple variable number of tandem repeat-based genotyping strategy for the detection of handling errors and validation of sample identity in biobanks. Biopreserv Biobank 14(5):383–389
https://www.neb.com/products/e7000-nebnext-direct-cancer-hotspot-panel#tabselect2
http://en.novogene.com/clinical-services/novopm-cancer-panels/
Li H, Durbin R (2009) Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics 25:1754–1760
Das K, Norton SE, Alt JR et al (2014) Stabilization of cellular RNA in blood during storage at room temperature: a comparison of cell-free RNA BCT((R)) with K3EDTA tubes. Mol Diagn Ther 18:647–653
Kang Q, Henry NL, Paoletti C et al (2016) Comparative analysis of circulating tumor DNA stability in K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem 49(18):1354–1360
Chabon JJ, Simmons AD, Lovejoy AF et al (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815
Sundaresan TK, Sequist LV, Heymach JV et al (2016) Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 22:1103–1110
Acknowledgments
This work was supported by Iwate Medical University Keiryokai Collaborative Research Grants (#125 for K.A.S. and #131 for S.S.N.) and JSPS KAKENHI (Grant Number JP16H01578 for S.S.N).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Nishizuka, S.S., Sato, K.A., Hachiya, T. (2019). A Pipeline for ctDNA Detection Following Primary Tumor Profiling Using a Cancer-Related Gene Sequencing Panel. In: Murray, S. (eds) Tumor Profiling. Methods in Molecular Biology, vol 1908. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9004-7_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9004-7_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9002-3
Online ISBN: 978-1-4939-9004-7
eBook Packages: Springer Protocols